Education/Professional Experience

2000 - 2003   M.S. of Clinical Oncology, Dalian Medical University

1986 - 1991   Bachelor of Medicine (Equivalent to M.D.), Chinese Medical University

2005. 09 - 2005.12 Department of integrated traditional and western medical oncology, China-Japan Friendship Hospital

2000.04-2000.06 Department ofHematological tumor, Harbin blood tumor research Institute

2016.10-2016-12  UAB Comprehensive Cancer Center, USA  

1991-   Department ofMedical Oncology, the First Affiliated Hospital of Dalian Medical University

Participation in the Academic Community

Member of Chinese Society of Clinical Oncology (CSCO)

Member of the standing committee of the world associationChinese oncologist

Member of China Research and Promotion of Traditional Chinese Medicine

Member of the standing committee of Professional committee of palliative care research of world federation ofChinese medicine society

Member of the standing committee of Chinese medicine education association of professional committee of lung cancer

Member of Institute of chemotherapy, Liaoning Province Anti-cancer Association

Publication

1.Zhou T, Zhang X, Dong Y, Zhuang F et,al. High-dose OxyContin to treat pain associated with bone metastasis in patients with small-cell lung cancer: a case study report.Drug Des Devel Ther. 2016 Jan 19;10:383-7. doi: 10.2147

2.Liu Suqin, Wang Hongjiang, Zhang Lizhi et al.Rapid detection of genetic mutations in individual breast cancer patients by next-generation DNA sequencing. Hum Genomics. 2015, 9(1): 2-12.  (Correspondence author)

3.Zhou Tao, Lv Ping, Liu Suqin et al. Effectiveness of gefitinib and relationship of EGFR mutation and VEGF expression in patients with lung adenocarcinoma. J Clinical Pulmonary Diseases. 2012, 17(12): 2233-2234.

4.Zhang Jing, Liu Suqin, Zhang Jie et al.Effectiveness and cost benefit analysis of different regimenin patients with advanced NSCLC. Journal of Chinese Clinical Oncology, 2012, 17(10): 908-911. (Correspondence author)

5.Zhang Lei, Liu Suqin，WangQuandong et al.Relationship of platin-based chemotherapy and peripheral blood Expression of ERCC1 in patients with advanced NSCLC. Journal of Clinical meta-analysis，2012, 27(18) 1575-1579. (Correspondence author)

Research Projects/Grants

1.2014-2016 Chemotherapy sensitive genes and prognosis in patients with postoperative lung adenocarcinoma. Project of Wu Jieping Foundation

2.2010-2013 Biomolecular analysis of Adjuvant targeted therapy in patients with postoperative NSCLC. Dalian Bureau of science and technology fund

3.2009-2012 EGFR mutation status and small molecular targeted therapy in patients with lung adenocarcinoma. Liaoning Bureau of science and technology fund

Admission Plan/Requirements

2 persons/ smart and dedicated to medical oncology